A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis

NCT06478706 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: ETD001
DRUG: Placebo

Sponsor

Enterprise Therapeutics Ltd